2023-01-27 | 71 patients have completed the SPARKLE study PDF Report Financial Data Presentation Webcast
2022-12-29 | 65 patients have completed the SPARKLE study PDF Report Financial Data Presentation Webcast
Regulatory 2022-12-06 | New Strong Orviglance Data Support Successful SPARKLE Completion with Substantially Fewer Patients PDF Report Financial Data Presentation Webcast
Regulatory 2022-12-02 | Nomination Committee appointed for AGM 2023 in Ascelia Pharma AB PDF Report Financial Data Presentation Webcast
2022-11-30 | ASCELIA PHARMA PRESENTS RESULTS OF ORVIGLANCE FOOD EFFECT STUDY AT RSNA 2022 SHOWING STRONG LIVER ENHANCEMENT BOTH WITH LIGHT MEAL AND IN FASTING CONDITION PDF Report Financial Data Presentation Webcast
2022-10-05 | Ascelia Pharma expands its leadership team PDF Report Financial Data Presentation Webcast
2022-09-28 | Ascelia Pharma Announces Successful Final Results from Orviglance Hepatic Impairment Study PDF Report Financial Data Presentation Webcast
2022-08-11 | Ascelia Pharma to present Orviglance Food Effect Study at 2022 RSNA Annual Meeting PDF Report Financial Data Presentation Webcast
2022-06-20 | Ascelia Pharma appoints Déspina Georgiadou Hedin as new CFO PDF Report Financial Data Presentation Webcast
2022-06-01 | Results from Orviglance comparison study to gadolinium presented at ESGAR 2022 conference PDF PDF Report Financial Data Presentation Webcast
2022-05-31 | Ascelia Pharma second US patent for Oncoral (oral irinotecan) strengthens coverage PDF Report Financial Data Presentation Webcast
2022-05-10 | Ascelia Pharma’s Food Effect Study shows that Orviglance image enhancement of the liver is not reduced by light meal PDF Report Financial Data Presentation Webcast
Regulatory 2022-05-05 | Bulletin from the Annual General Meeting in Ascelia Pharma AB on 5 May 2022 PDF Report Financial Data Presentation Webcast
Regulatory 2022-04-05 | NOTICE OF ANNUAL GENERAL MEETING IN ASCELIA PHARMA AB PDF Report Financial Data Presentation Webcast
2022-04-01 | CFO Kristian Borbos to leave Ascelia Pharma PDF Report Financial Data Presentation Webcast
2022-03-22 | New independent market research says 84% US healthcare professionals likely to use Orviglance imaging agent in target population PDF PDF Report Financial Data Presentation Webcast
2022-03-11 | Ascelia Pharma successfully completes Orviglance Hepatic Impairment Study PDF Report Financial Data Presentation Webcast
Regulatory 2022-03-07 | Ascelia Pharma suspends clinical activities in Russia PDF Report Financial Data Presentation Webcast
